SCHEMBL1978719

SCHEMBL1978719

COc1cc(C(C)(C)C(=O)C[N+](=O)[O-])ccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
MAPT P10636 4/20 0.38
RORC P51449 1/20 0.38
THRB P10828 1/20 0.37
RIPK2 O43353 1/20 0.37
LMNA P02545 3/20 0.36
CNR2 P34972 1/20 0.36
KMO O15229 1/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
MAPK1 P28482 2/20 0.36
HTT P42858 1/20 0.36
FBP1 P09467 1/20 0.36
PTPN1 P18031 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
HPGD P15428 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL602550 0.88 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AL3MBTL1CYP1A2
SCHEMBL10227980 0.81 RIPK2 (0.42) ALDH1A1MAPTRIPK2LMNACNR2
SCHEMBL10227970 0.81 RIPK2 (0.39) ALDH1A1MAPTRIPK2LMNACNR2
SCHEMBL17434594 0.80 NR1H4 (0.43) ALDH1A1MAPTRIPK2LMNACNR2
SCHEMBL1978722 0.78 ALDH1A1 (0.38) ALDH1A1MAPTRORCTHRBLMNA
SCHEMBL602672 0.77 AKR1C3 (0.47) ALDH1A1MAPTRIPK2LMNACNR2
SCHEMBL10227971 0.77 KMO (0.43) ALDH1A1MAPTRIPK2LMNACNR2
SCHEMBL15383148 0.76 CNR2 (0.48) ALDH1A1MAPTRIPK2LMNACNR2
SCHEMBL10227951 0.76 ALDH1A1 (0.41) ALDH1A1MAPTLMNAMEN1KMT2A
SCHEMBL897967 0.75 CNR2 (0.46) ALDH1A1MAPTRIPK2CNR2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846739-B2 TGR5 agonists EXELIXIS PATENT COMPANY LLC (US) 2014-09-30 US disclosed
US-8846739-B2 TGR5 agonists EXELIXIS PATENT COMPANY LLC (US) 2014-09-30 US disclosed
US-8846739-B2 TGR5 agonists EXELIXIS PATENT COMPANY LLC (US) 2014-09-30 US disclosed
US-20130303505-A1 TGR5 AGONISTS EXELIXIS PATENT COMPANY LLC 2013-11-14 US disclosed
US-20130303505-A1 TGR5 AGONISTS EXELIXIS PATENT COMPANY LLC 2013-11-14 US disclosed
US-20130303505-A1 TGR5 AGONISTS EXELIXIS PATENT COMPANY LLC 2013-11-14 US disclosed
EP-2509960-A1 TGR5 AGONISTS Exelixis, Inc. (US) 2012-10-17 EP disclosed
WO-2011071565-A1 TGR5 AGONISTS EXELIXIS, INC. (US) 2011-06-16 WO disclosed
WO-2011071565-A1 TGR5 AGONISTS EXELIXIS, INC. (US) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303505-A1 TGR5 AGONISTS GCGR, NPY5R, TBXA2R ALDH1A1 3462/4885MAPT 3994/4885RORC 1228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.